No. |
Variant name |
Chromosome position |
Chromatin state |
Related regulatory elements |
Target genes |
Extended variants |
Associated traits |
1 |
rs576709665 |
chr1:213546417-213546418 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
2 |
rs376434707 |
chr1:213546450-213546451 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
3 |
rs543753431 |
chr1:213546611-213546612 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
4 |
rs557323388 |
chr1:213546690-213546691 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
5 |
rs561794589 |
chr1:213546721-213546722 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
6 |
rs142212320 |
chr1:213546722-213546723 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
7 |
rs12407494 |
chr1:213546851-213546852 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
8 |
rs12407238 |
chr1:213546852-213546853 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
9 |
rs61308735 |
chr1:213546890-213546891 |
Weak transcription Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
10 |
rs112172934 |
chr1:213546896-213546897 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
11 |
rs151228658 |
chr1:213546946-213546947 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
12 |
rs551582431 |
chr1:213546968-213546969 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
13 |
rs569734007 |
chr1:213547006-213547007 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
14 |
rs1187781 |
chr1:213547097-213547098 |
Weak transcription Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
15 |
rs139144420 |
chr1:213547154-213547155 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
16 |
rs567271690 |
chr1:213547163-213547164 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
17 |
rs149941356 |
chr1:213547165-213547166 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
18 |
rs187823087 |
chr1:213547170-213547171 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
19 |
rs577782147 |
chr1:213547218-213547219 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
20 |
rs1187780 |
chr1:213547278-213547279 |
Weak transcription Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
mRNA abundance
|
21 |
rs558372694 |
chr1:213547289-213547290 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
22 |
rs79936850 |
chr1:213547414-213547415 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
23 |
rs146442571 |
chr1:213547426-213547427 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
24 |
rs372444658 |
chr1:213547501-213547502 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
25 |
rs573712669 |
chr1:213547534-213547535 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
26 |
rs575914273 |
chr1:213547594-213547595 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
27 |
rs140908566 |
chr1:213547598-213547599 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
28 |
rs559301629 |
chr1:213547625-213547626 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
29 |
rs567394691 |
chr1:213547672-213547673 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
30 |
rs34551641 |
chr1:213547685-213547686 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
31 |
rs536439441 |
chr1:213547773-213547774 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
32 |
rs545161659 |
chr1:213547809-213547810 |
Weak transcription Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
33 |
rs201484166 |
chr1:213547884-213547885 |
Weak transcription Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
34 |
rs144587269 |
chr1:213547886-213547887 |
Weak transcription Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
35 |
rs546298372 |
chr1:213547964-213547965 |
Weak transcription Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
36 |
rs539608032 |
chr1:213547994-213547995 |
Weak transcription Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
37 |
rs192163155 |
chr1:213547996-213547997 |
Weak transcription Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
38 |
rs567529482 |
chr1:213548009-213548010 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
39 |
rs528113729 |
chr1:213548016-213548017 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
40 |
rs569971035 |
chr1:213548060-213548061 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
41 |
rs375706239 |
chr1:213548062-213548063 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
42 |
rs146671128 |
chr1:213548067-213548068 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
43 |
rs116493979 |
chr1:213548070-213548071 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
44 |
rs556737157 |
chr1:213548082-213548083 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
45 |
rs367656338 |
chr1:213548094-213548095 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
46 |
rs11576556 |
chr1:213548168-213548169 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
47 |
rs1211362 |
chr1:213548175-213548176 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
48 |
rs148833218 |
chr1:213548190-213548191 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
49 |
rs555662012 |
chr1:213548193-213548194 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
50 |
rs74142106 |
chr1:213548224-213548225 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|